Acadian Asset Management
NRIX icon

Acadian Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Acadian Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-42,755
Closed -$393K – 2077
2025
Q3 		$393K Buy
+42,755
New +$444K ﹤0.01% 1269
2024
Q4 		– Sell
-106,861
Closed -$2.4M – 2001
2024
Q3 		$2.4M Sell
106,861
-8,480
-7% -$192K 0.01% 693
2024
Q2 		$2.41M Sell
115,341
-44,952
-28% -$700K 0.01% 702
2024
Q1 		$2.35M Buy
160,293
+136,606
+577% +$1.47M 0.01% 623
2023
Q4 		$244K Buy
+23,687
New +$162K ﹤0.01% 1196

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management's NRIX Position: Q4 2025 in Review

Acadian Asset Management sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 42,755 shares — an estimated $393K sold.

Acadian Asset Management first reported a position in NRIX in Q4 2023 and held it in 5 quarters. The position peaked at $2.41M in Q2 2024. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • Acadian Asset Management reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Acadian Asset Management sold 42,755 Nurix Therapeutics shares in Q4 2025, an estimated $393K.
  • Acadian Asset Management first reported a position in Nurix Therapeutics in Q4 2023 and held it in 5 quarters.
  • Acadian Asset Management's Nurix Therapeutics position peaked at $2.41M in Q2 2024.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Acadian Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.